Alejandro Hernandez, MD
Undersea and Hyperbaric Medicine · Mercedes, TXNPI 1871908178
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Organogenesis Inc. at 28.0% of the total. Reporting peaked in 2021 at $1,365 and has fallen 64.7% since, to $482 in 2025.
Across 163 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$1K
- Smith+Nephew$1K
- Hydrofera LLC$301
- KCI USA, Inc.$287
- Tactile Systems Technology Inc$221
- Melinta Therapeutics, LLC$204
- plus $1K from 14 others
What the payments were for
- Food & beverage$4,444100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 32 | $1,243 |
| Smith+Nephew | 64 | $1,082 |
| Hydrofera LLC | 14 | $301 |
| KCI USA, Inc. | 4 | $287 |
| Tactile Systems Technology Inc | 11 | $221 |
| Melinta Therapeutics, LLC | 5 | $204 |
| AbbVie(2 entities) | 7 | $201 |
| Urgo Medical North America, LLC | 5 | $160 |
| Sechrist Industries Inc | 1 | $155 |
| Lilly USA, LLC | 2 | $143 |
| Pfizer | 1 | $118 |
| Reprise Biomedical, Inc. | 1 | $116 |
| Paratek Pharmaceuticals, Inc. | 4 | $69 |
| Aroa Biosurgery Incorporated | 4 | $34 |
| Lifenet Health | 2 | $33 |
| Axonics, Inc. | 1 | $23 |
| Cashflow Solutions, LLC | 2 | $16 |
| Solventum Corporation | 1 | $15 |
| Bioventus LLC | 1 | $14 |
| Amniox Medical, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Affinity$272
- Apligraf$256
- PuraPly$240
- PURAPLY WOUND MATRIX$147
- SNAP$125
- Grafix PRIME$125
- Grafix CORE$125
- Grafix XC$125
- Grafix PL PRIME$125
- Stravix$125
- VAC VERAFLO$125
- PREVENA$125
- KISUNLA$125
- HYDROFERA BLUE$119
- ELIQUIS$118
- Baxdela$116
- VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP$115
- DRAWTEX HYDROCONDUCTIVE WOUND DRESSING WITH LEVAFIBER 4X4$115
- UrgoK2$115
How this compares
$4,444 in reported general payments places this provider in the 75th percentile of 59 undersea and hyperbaric medicine providers in Texas.
See all undersea and hyperbaric medicine providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 64 | $80,242 |
| OzempicSemaglutide | 16 | $19,853 |
| Gentamicin Sulfate | 129 | $6,534 |
| MyrbetriqMirabegron | 11 | $5,244 |
| SsdSilver Sulfadiazine | 101 | $2,699 |
| Mupirocin | 156 | $2,185 |
| Permethrin | 15 | $1,462 |
| Doxycycline Hyclate | 61 | $916 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 18 | $715 |
| Clindamycin Hcl | 55 | $695 |
| Ibuprofen | 17 | $608 |
| Triamcinolone Acetonide | 44 | $562 |
| Omeprazole | 25 | $426 |
| Silver Sulfadiazine | 18 | $313 |
| Clotrimazole | 11 | $311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,082 | $80,24264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 59 undersea and hyperbaric medicine providers in Texas.
Other undersea and hyperbaric medicine in Mercedes
- Wade FarrowCollege Station$2.2M
- Timothy BumannAbilene$154K
- Heather AguirreSan Antonio$98K
- Ronald ScottFrisco$76K
- Andrew ApplewhiteDallas$46K
- Joseph WolcottLubbock$38K
- Noel OliveiraEdinburg$33K
- Maria AguinagaMission$18K
- Jayesh ShahSan Antonio$17K
- Marcus GitterleNew Braunfels$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.